Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
293,061,432
-
Total 13F shares
-
117,984,795
-
Share change
-
+6,328,611
-
Total reported value
-
$1,259,732,308
-
Put/Call ratio
-
41%
-
Price per share
-
$10.65
-
Number of holders
-
160
-
Value change
-
+$77,596,210
-
Number of buys
-
107
-
Number of sells
-
46
Institutional Holders of AbCellera Biologics Inc. - Ordinary Shares (ABCL) as of Q2 2022
As of 30 Jun 2022,
AbCellera Biologics Inc. - Ordinary Shares (ABCL) was held by
160 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
117,984,795 shares.
The largest 10 holders included
BAILLIE GIFFORD & CO, Capital World Investors, BlackRock Inc., Allianz Asset Management GmbH, BAKER BROS. ADVISORS LP, ORBIMED ADVISORS LLC, HARVARD MANAGEMENT CO INC, RENAISSANCE TECHNOLOGIES LLC, GUARDIAN CAPITAL ADVISORS LP, and Founders Fund VII Management, LLC.
This page lists
160
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.